

CTAD 2010

Clinical Trials on Alzheimer's Disease

Montpellier '08 | Las Vegas '09 | Toulouse '10 | San Diego '11

Clinical Trials on Alzheimer's Disease

CTAD
Toulouse
2010

November 3-5, 2010

Toulouse
Hôtel-Dieu Saint Jacques

 **IPSEN**
Innovation for patient care

 **Janssen**
A Division of Janssen Pharmaceutica

 **Lilly**

 **EADC**

 **Lundbeck**

 **NOVARTIS**

 **Pfizer**

European Alzheimer's Disease Consortium
Montpellier and Toulouse EADC Centers

 **GÉRONTOPÔLE**

<http://www.ctad.fr>

CTAD Congress secretariat : ctad@ant-congres.com

Clinical Trials

Dear Colleague,

After the huge success of our 2nd edition of CTAD 2009 this past October in Las Vegas, we are proud to present our exciting final program for our 3rd edition CTAD which will take place in Toulouse, France on November 3-5, 2010.

As you will see CTAD 2010 is bringing together the current leaders involved in clinical trials on Alzheimer's Disease to discuss new results, new drugs development and future methodological issues (disease modifying outcomes, biomarkers, impact on the Healthcare economy...). This conference will bring you the latest knowledge on AD clinical trials based on the clinical experiences of international teams. This will be the perfect occasion to exchange with your peers on this topic and take home some hands-on therapeutic and methodological tools to improve and reinforce your AD clinical trials teams.

Looking forward to seeing you in Toulouse!!

Paul Aisen - Jacques Touchon - Bruno Vellas - Michael Weiner

Clinical Trials on Alzheimer's Disease

SCIENTIFIC COMMITTEE

Paul AISEN (San Diego)
 Kaj BLENNOW (Moindal)
 Merce BOADA (Barcelona)
 Maria CARRILLO (Chicago)
 Bruno DUBOIS (Paris)
 Howard FELDMAN (Vancouver)
 Giovanni B. FRISONI (Brescia)
 Lutz FROELICH (Mannheim)
 Serge GAUTHIER (Montreal)
 Ezio GIACOBINI (Geneva)
 Michael GRUNDMANN (San Diego)
 Zaven KHACHATURIAN (Washington DC)
 Virginia LEE (Philadelphia)
 Jean-Marc ORGOGOZO (Bordeaux)
 Ronald PETERSEN (Minnesota)
 Lon SCHNEIDER (Los Angeles)
 Eric SIEMERS (Philadelphia)
 Peter SNYDER (Rhode Island)
 Yaakov STERN (New York)
 Jacques TOUCHON (Montpellier)
 John TROJANOWSKI (Philadelphia)
 Bruno VELLAS (Toulouse)
 Michael W. WEINER (San Francisco)
 Bengt WINBLAD (Stockholm)

ORGANIZING COMMITTEE

Paul AISEN
 Merce BOADA
 Zaven KACHATURIAN
 Jacques TOUCHON
 Bruno VELLAS
 Michael WEINER

CONGRESS SECRETARIAT

ANT Congrès
 154 avenue de Lodève - 34070 Montpellier France
 E-mail : ctad@ant-congres.com
 Phone : + 33 (0)4 67 10 92 23

CONTENT

Program	p. 2 - 6
Program at a glance	p. 2
Wednesday, November 3 rd	p. 3 - 4
Thursday, November 4 th	p. 4 - 6
Friday, November 5 th	p. 7-11
Posters	p. 12-19
Sponsors	p. 20
General Informations	p. 21

PROGRAM AT A GLANCE

Tuesday, November 2nd12.00 - 4.00 p.m. EADC SYMPOSIUM (Members only) - *Chapelle Room***Wednesday, November 3rd****PRE-CTAD CONGRESS**9.00 a.m - 5.00 p.m. LEON THAL SYMPOSIUM - *Gaspard de Maniban Room*EADC SYMPOSIUM (Members only) - *Chapelle Room*8.30 a.m - 4.05 p.m. ALZHEIMER'S DRUG DISCOVERY FOUNDATION FORUM - *Les Colonnnes Room***CTAD CONGRESS**5.00 - 6.00 p.m. INTRODUCTION AND WELCOME KEYNOTE - *Les Colonnnes Room*6.00 - 7.00 p.m. LEON THAL PANEL DISCUSSION - *Les Colonnnes Room*7.15 p.m. WELCOME RECEPTION - *Off Site - City Hall Place du Capitole***Thursday, November 4th**7.30 - 8.30 a.m. PANEL DISCUSSION - *Les Colonnnes Room*8.30 - 10.30 a.m. **PRE DEMENTIA ALZHEIMER TRIALS** - *Les Colonnnes Room**Coffee Break and poster session*11.00 - 12.45 p.m. **PREVENTIVE TRIALS IN ALZHEIMER'S DISEASE** - *Les Colonnnes Room**Lunch break*1.30 - 2.30 p.m. PANEL DISCUSSION - *Les Colonnnes Room*2.30 - 4.00 p.m. SYMPOSIUM - *Les Colonnnes Room**Coffee Break and poster session*4.30 - 7.00 p.m. SYMPOSIA - *Les Colonnnes Room***Friday, November 5th**8.00 - 10.30 a.m. **NEW THERAPY TRIALS IN AD** - *Les Colonnnes Room**Coffee Break and poster session*11.00 - 12.20 p.m. **OTHER ASPECTS FOR CLINICAL TRIALS IN AD** - *Les Colonnnes Room**Lunch break*1.20 - 4.30 p.m. ORAL COMMUNICATIONS : Biomarkers - *Les Colonnnes Room* Methodological aspects and Treatment issues - *Chapelle Room*3.35 p.m. *Coffee Break and poster session*4.45 p.m. **CLOSING KEYNOTE** - *Les Colonnnes Room*

PRE-CTAD CONGRESS

9.00 a.m - 5.00 p.m	LEON THAL SYMPOSIUM <small>Gaspard de Maniban Room</small> EADC SYMPOSIUM (Members only) <small>Chapelle Room</small>
8.30 a.m - 4.05 p.m	ALZHEIMER'S DRUG DISCOVERY FOUNDATION FORUM <small>Les Colonnnes Room</small> <i>The Alzheimer's Drug Discovery Foundation (ADDF) presents - Feeding the Pipeline: Novel Drug Discovery for Alzheimer's disease : The purpose of this meeting is to present exciting drug discovery efforts in the field of Alzheimer's disease being conducted by early-stage European biotechnology companies. There will be ample opportunity for discussion, sharing of ideas and networking.</i>
8.30 - 8.40 a.m	Introduction and Opening Remarks : Howard Fillit, MD, <i>ADDF</i>
8.40 - 9.20 a.m	Plenary Talk : Developing disease modifying therapy for Alzheimer's disease : Rachel J. Schindler, MD, <i>Pfizer Inc.</i>
9.20 - 9.50 a.m	Alzheimer's program : Lars U. Wahlberg, MD, PhD, <i>NSGene</i>
9.50 - 10.20 a.m	SEN1176 inhibits A β -induced macrophage activation and protects against learning and memory deficits caused by aggregated A β 1-42 : Hozefa Amijee, PhD, <i>Senexis Limited</i>
10.20 - 10.40 a.m	<i>Break</i>
10.40 - 11.10 p.m	First in class disease modifying drugs for Alzheimer's disease : Speaker TBD, <i>Oryzon</i>
11.10 - 11.40 p.m	A new class molecule AZP2006 redirects APP metabolism toward the non-amyloidogenic pathway : Cecilia Estrella, PhD, <i>AlzProtect</i>
11.40 - 12.10 p.m	<i>Discovery and development of first-in-class modifiers of Alzheimer's disease</i> Gerard Griffioen, PhD, <i>reMYND</i>
12.10 - 1.30 p.m	<i>LUNCH - on site</i>
1.30 - 2.00 p.m	AD vaccine program : Speaker TBD, <i>AC Immune</i>
2.00 - 2.30 p.m	Cogane for Alzheimer's disease: a neuroprotective strategy : Patrick Howson, PhD, <i>Phytopharm</i>
2.30 - 3.00 p.m	Novel funding models for drug discovery : Andrea W. Tobias, PhD, <i>Aquila Consulting Group</i>
3.00 - 3.20 p.m	<i>Break</i>
3.20 - 4.00 p.m	PANEL : Funding Climate for Biotechnology Companies <i>Chair: Andrea W. Tobias, PhD, Aquila Consulting Group - Pharma: Laurent Pradier, PhD, Sanofi-Aventis - Venture Capital: Philippe Peltier, Auriga Partners Government: Bernard Meunier, PhD, Palumed - Foundation: Howard Fillit, MD, Alzheimer's Drug Discovery Foundation</i>
4.00 - 4.05 p.m	Closing Remarks : Howard Fillit, <i>ADDF</i>

Wednesday, November 3rd - Continued

CTAD CONGRESS

5.00 - 5.15 p.m	WELCOME AND INTRODUCTION - <i>P.Aisen, Z.Kachaturian, J.Touchon, B.Vellas</i>	Les Colannes Room
	OPENING KEYNOTE	
5.15 - 6.00 p.m	Designing primary prevention trial using biomarkers <i>M.Weiner, University of California San Francisco, USA</i>	
6.00 - 7.00 p.m	LEON THAL PANEL DISCUSSION <i>Z.Kachaturian, President & Chair, PAD2020: The Campaign to Prevent Alzheimer's Disease by 2020, Washington, DC, USA</i>	Les Colannes Room
7.15 p.m	WELCOME RECEPTION - <i>City Hall - Place du Capitole</i>	

Thursday, November 4th

7.30 - 8.30 a.m	PANEL DISCUSSION REDEFINING ALZHEIMER'S DISEASE: Revising the NINCDS-ADRDA Criteria Chaired by <i>M. Carillo, Alzheimer Association, USA, P.Snyder, Lifespan Affiliated Hospitals, USA</i> Criteria for Alzheimer's Disease Dementia <i>D.Knopman, Mayo Clinic, USA</i> Criteria for Symptomatic Pre-Dementia Alzheimer's Disease <i>R.Petersen, Mayo Clinic, USA</i> Criteria for Preclinical Alzheimer's Disease Dementia <i>R.Sperling, Harvard Medical School, USA</i>	Les Colannes Room
-----------------	---	-------------------

PRE DEMENTIA ALZHEIMER TRIALS chaired by *H.Feldman, University of British Columbia, Canada*

8.30 - 9.00 a.m	Incorporating amyloid imaging in current and/or future collaborative research studies <i>C.Clark, University of Pennsylvania, USA</i>	Les Colannes Room
9.00 - 9.30 a.m	Re-thinking Alzheimer's Disease therapy; lessons learned from ongoing clinical trials <i>B.Winblad, KI-Alzheimer Disease Research Center (KI-ADRC), Sweden</i>	
9.30 - 10.00 a.m	Results of the VITACOG trial of homocysteine-lowering B vitamins in subjects with MCI <i>D.Smith, University of Oxford, U.K, H.Refsum, University of Oslo, Norway</i>	
10.00 - 10.30 a.m	Presymptomatic Tests for AD and the Search for Mechanism <i>M.J.de Leon et al, New York University Medical Center, USA</i>	
10.30 - 11.00 a.m	Coffee Break and poster session	

Thursday, November 4th - Continued

PREVENTIVE TRIALS IN ALZHEIMER'S DISEASE

chaired by C.Sampaio, *University of Lisbon, Portugal*, E.Siemers, *Lilly Corporate Center, USA*

Les Colonnnes Room

11.00 - 11.30 a.m Designing secondary Preventive trials

P.Aisen, University of California San Diego, USA

11.30 - 12.00 p.m First results of the PERFORM-Dementia Study : 3-year Incident Dementia in 19 000 post-stroke patients

J.M.Orgogozo et al, CHU Bordeaux, France

12.00 - 12.30 p.m GUIDAGE : Results from the guidage Study

B.Vellas, CHU Toulouse, France

12.30 - 12.45 p.m Update on the semagacestat program

E.Siemers, Alzheimer's Disease Team, Lilly Corporate Center, USA

12.45 - 1.30 p.m

Lunch break

1.30 - 2.30 p.m

PANEL DISCUSSION : Stratification of AD patients and inclusion of CSF biomarkers in clinical trials

Les Colonnnes Room

1. *Subgroups of AD based on Clinical and imaging findings*

P.Scheltens, VU University Medical Center, The Netherlands

2. *CSF biomarkers for diagnosis and monitoring*

H.Hampel, Goethe University, Germany

3. *Different etiopathogenic mechanisms and subgroups of AD based on CSF molecular markers*

K.Iqbal, NY State Institute for Basic Research In Developmental Disabilities, USA

4. *Why most AD trials fail*

P.Aisen, University of California San Diego, USA

5. *Cost analysis of using pure AD patients versus AD with mixed pathologies in clinical trials*

A.Wimo, Karolinska Institutet, Huddinge, Sweden

6. *Stratify or not stratify*

L.Altstiel, Pfizer, USA

Thursday, November 4th - Continued

SYMPOSIA

Les Colonnnes Room

2.30 - 4.00 p.m

1st Symposium : Simulating Clinical Trials for AD and MCI (in order to design them better)

1- Overview

L. Schneider, University of Southern California, USA

2- Model-based AD drug development and clinical trials: key concepts and examples from early and late development

B. Corrigan, Pfizer, USA

3- Understanding the placebo response in AD clinical trials

K.Ito, Pfizer, USA

4- Simulations of prodromal AD (aMCI) trials to determine the effect of CSF amyloid-beta42 biomarkers on efficiency and clinical outcomes

L. Schneider

Discussant, H.Hampel, Goethe University, Germany

4.00 - 4.30 p.m

Coffee Break and poster session

4.30 - 6.00 p.m

2nd Symposium : «A Standardized Re-Assessment of Cognitive Instrumentation Used in Clinical Trials for MCI»

1- *The PAD2020 Survey of Cognitive Instrumentation Used in Clinical Trials for MCI & Prodromal AD*

P.J.Snyder, Warren Alpert Medical School of Brown University, USA

2- *Developing the ADAS-Cog to enhance its measurement performance for clinical trials of MCI*

J.Hobart, Derifford Hospital, UK

3- *How, When and Why to Develop a New Generation of Cognitive Instruments for Clinical Trials*

Y.Stern, Columbia University, USA

4- *Round-Table Panel Discussion*

P.J.Snyder, Y.Stern, P.Maruff, K.Wesnes, J.Hobart

6.00 - 7.00 p.m

3rd Symposium : Clinical trials for Secondary prevention of AD: What is the current evidence

- Methodological issues
- Target population
- Outcome parameters
- Biometrical issues
- G.Biloba - Estrogens - NSAIDs

Co-chaired by : L.Frölich, CIMH Mannheim, Germany, I.Heuser, Humboldt University, Germany

Friday, November 5th

NEW THERAPY TRIALS IN AD

chaired by G.Frisoni, *IRCCS San Giovanni di Dio, Italy*, S.Gauthier, *McGill University, Canada*

Les Colonnnes Room

8.00 - 8.30 a.m

Autoimmune trials in AD

R.Dodel, University of Marburg, Germany

8.30 - 9.00 a.m

Lithium trial in AD

H.Hampel, Goethe University, Germany

9.00 - 9.30 a.m

Tau-focused therapies in clinical trials

S.Whitaker, Allon therapeutics, USA TBC

9.30 - 10.00 a.m

Development Update on Dimebon in AD & HD

B.Winblad, Karolinska Institutet, Sweden

10.00 - 10.30 a.m

Current Clinical Development Strategy: What have we learned in the past 5 years ?

S.Hendrix, Pentara Corporation, USA

10.30 - 11.00 a.m

Coffee Break and poster session

OTHER ASPECTS FOR CLINICAL TRIALS IN AD

chaired by E.Giacobini, *Geneva, Switzerland*, Z.Kachaturian, *Washington DC, USA*

Les Colonnnes Room

11.00 - 11.20 a.m

PLASA: Results from the Plasa Study

F.Nourashemi, CHU Toulouse, France

11.20 - 11.40 a.m

Quality of life and clinical trials: data from the Plasa study

N.Coley, S.Andrieu, CHU Toulouse, France

11.40 - 12.00 p.m

Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease

H.Fillit, Alzheimer's Drug Discovery Foundation (ADDF) USA

12.00 - 12.20 p.m

Impact of the action of the French «National Center for management of trials on health products»

P.J.Ousset, CHU Toulouse, J.Touchon, CHU Montpellier, V.Diebolt, CENGEPs Lyon, France

12.20 - 1.20 p.m

Lunch break

Friday, November 5th

7

1.20 p.m

ORAL COMMUNICATIONS

THEME: Methodological aspects and treatment issues

Chaired by M.Boada, A.D.Roses

Chapelle Room

1.20 p.m

- O1** DOMINANTLY INHERITED ALZHEIMER'S NETWORK TREATMENT TRIALS INITIATIVE AT CTAD
R.Bateman

1.35 p.m

- O3** DIETARY MANAGEMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT
J.Kuo, Adeona Pharmaceuticals, USA

1.50 p.m

- O5** SUITABILITY OF THE CLINICAL DEMENTIA RATING-SUM OF BOXES AS A SINGLE PRIMARY ENDPOINT FOR ALZHEIMER'S DISEASE TRIALS
N.Coley (1), S.Andrieu (1,2), M.Jaros (3), M.Weiner (4), J.Cedarbaum (3), B.Vellas (1,5)
(1) INSERM U558, University of Toulouse III, France
(2) CHU Toulouse, Toulouse, France
(3) Elan Pharmaceuticals, South San Francisco, CA, USA
(4) University of California, San Francisco; Department of Veterans Affairs Medical Center, San Francisco, CA, USA
(5) CHU Toulouse, Department of Geriatric Medicine, Alzheimer Centre, Gerontopole, Toulouse, France

THEME: Biomarkers

Chaired by P.Robert, L.Frölich

Les Colonnnes Room

- O2** HIPPOCAMPUS COLLABORATIVE STUDY: DESIGN AND FIRST RESULTS
B.Dubois (1), M.Sarazin (1), C.Dufouil (1), S.Lehericy (1), M.Chupin (1), I.Tonelli (1), L.Garnero (1), D.Dormont (1), B.Croisille (4), J.Touchon (2), P.Robert (3)
(1) Paris, France, (2) Montpellier, France, (3) Nice, France, (4) Lyon, France

- O4** CORRELATIONS BETWEEN SOLUBLE A/B FORMS OF AMYLOID PRECURSOR PROTEIN AND AB38, 40 AND 42 IN HUMAN CEREBROSPINAL FLUID
A.Gabelle (1,2,3), S.Roche (4), C.Gény (1), K.Bennys (1), P.Labauge (5), Y.Tholance (6), I.Quadrio (6), L.Tiers (4), B.Gor (4), C.Chaulet (1), A.Vighetto (6,8), B.Croisile (6,8), P.Krolak-Salmon (7,8), J.Touchon (1,2,9), A.Perret-Liaudet (6), S.Lehmann (2,3,4)
(1) CMRR Montpellier, Hôpital Gui de Chaillac, Montpellier (2) Université Montpellier1, Faculté de Médecine, Montpellier (3) UPR 1142, CNRS, Institut de Génétique Humaine, Montpellier (4) CHU Saint Eloi, Montpellier (5) Service de Neurologie, CHU de Nîmes, Hôpital Caremeau, Nîmes (6) Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Bron
(7) Hôpital des Charpennes, 27, Hospices Civils de Lyon, Villeurbanne
(8) Centre Mémoire Recherche Ressources Lyon, Hospices Civils, Lyon
(9) INSERM U888, Hôpital de la Colombière, Montpellier, France

- O6** AMYLOID LOWERING TREATMENT AND NEUROIMAGING FINDINGS: WHICH PATH FORWARD ?
H.Feldman
University of British Columbia, Canada

ORAL COMMUNICATIONS

THEME: Methodological aspects and treatment issues

Chaired by M.Boada, A.D.Roses

Chapelle Room

THEME: Biomarkers

Chaired by P.Robert, L.Frölich

Les Colannes Room

2.05 p.m

O7 OXIDATIVE STRESS-INDUCED BRAIN HYPOMETABOLISM UNDERLIES THE PATHOPHYSIOLOGY OF ALZHEIMER DISEASE AND OFFERS NEW AND SUCCESSFUL TARGETS FOR TREATMENT: ASTONISHING THERAPEUTICS EFFECTS FROM A COMBINATION OF A MELANIN PRECURSOR (QIAPI-1) AND SELECTIVE MITOCHONDRIAL ANTIOXIDANTS (ALCAR+LA): NEW SCENT ON THE TRAIL?
G.Aliev (1,2,3), H.H.Palacios (4), J.Leszek (4), M.E.Obrenovich (5), V.Bragin (2), A.Solis Herrera (6)
 (1) University of Atlanta, Atlanta Georgia, USA
 (2) Stress Relief Center, Brooklyn, NY, USA
 (3) Department of Biology, University of Texas, San Antonio, USA
 (4) Department of Psychiatry, Wroclaw Medical University, Poland
 (5) Case Western Reserve University, Cleveland, Ohio, USA
 (6) Centro Estudios de Fotosíntesis Humana.S.C., Aguascalientes, México

O8 ENRICHMENT THROUGH BIOMARKERS IN CLINICAL TRIALS OF ALZHEIMER'S DRUGS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT
M.Lorenzi (1), M.Donohue (2), D.Paternicò (1), C.Scarpazza (1), S.Ostrowitzki (3), O.Blin (4), E.Irving (5), G.B.Frisoni (1,6), The Alzheimer's Disease Neuroimaging Initiative
 (1) LENITEM Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS San Giovanni di Dio-FBF, Brescia, Italy
 (2) Division of Biostatistics and Bioinformatics, University of California, San Diego, USA
 (3) Translational Medicine, Neuroscience, F. Hoffmann-La Roche Ltd, Basel, Switzerland
 (4) Clinical Investigation Centre (CIC-UPCET) and Department of Clinical Pharmacology, UMR-CNRS, 6193 Institute of Cognitive Neurosciences, CHU, Timone, Marseille, France
 (5) Neurosciences CEDD, GlaxoSmithKline, Harlow, Essex, UK
 (6) AfAR Associazione Fatebenefratelli per la Ricerca, Rome, Italy

2.20 p.m

O9 A LARGE-SCALE RANDOMIZED CLINICAL TRIAL OF VITAMIN D AND EPA/DHA FOR PREVENTION OF COGNITIVE DECLINE IN A MULTI-ETHNIC POPULATION: THE VITAL-COG TRIAL
F.Grodstein, J.E.Manson, J.H.Kang
 Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

O10 VALIDATION OF FLORBETAPIR-PET FOR IMAGING ALZHEIMER'S DISEASE AMYLOID PATHOLOGY: A PROSPECTIVE MULTICENTER CLINICO-PATHOLOGIC CORRELATIVE STUDY
D.M.Skovronsky, C.M.Clark, J.A.Schneider, B.J.Bedell, T.G.Beach, M.A.Mintun, M.J.Pontecorvo, F.Hefti, A.P.Carpenter, M.L.Flitter, M.J.Krautkramer, H.F.Kung, R.E.Coleman, M.Doraiswamy, A.S.Fleischer, M.N.Sabbagh, C.H.Sadowsky, P.E.M.Reiman, and the AV45-A07 study group.
 Philadelphia; Chicago; Montreal Quebec; Phoenix; Washington; Durham; San Diego; Ft. Lauderdale

Friday, November 5th

2.35 p.m

ORAL COMMUNICATIONS

THEME: Methodological aspects and treatment issues

Chaired by M.Boada, A.D.Roses

Chapelle Room

2.35 p.m

- O11** DOES B VITAMIN TREATMENT SLOW COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT FOR THOSE WITH RAISED PLASMA HOMOCYSTEINE? A RANDOMIZED CONTROLLED TRIAL (VITACOG)
C.A.De Jager (1), A.Oulhaj (1), R.Jacoby (2), H.Refsum (3,4), A.D.Smith (3)

(1) OPTIMA, Nuffield Department of Medicine, University of Oxford, Oxford, UK

(2) University Department of Psychiatry, Warneford Hospital, Oxford, UK

(3) OPTIMA, B vitamin Laboratory, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK,

(4) Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway

2.50 p.m

- O13** A PILOT CLINICAL TRIAL ON ALZHEIMER'S DISEASE WITH THE GSK-3 INHIBITOR NYPTA® (TIDEGLUSIB)
T.Del Ser

Noscira SA, Tres Cantos, Madrid, Spain

3.05 p.m

- O15** CLINICAL ASSESSMENT USING INFORMATION AND COMMUNICATION TECHNOLOGIES IN ALZHEIMER DISEASE: INTEREST FOR CLINICAL TRIALS

P.H.Robert, R.Romdhane, F.Bremont, E.Mulin
CMRR & Nice, France INRIA Pulsar, Sophia Antipolis, France

THEME: Biomarkers

Chaired by P.Robert, L.Frölich

Les Colonnnes Room

- O12** HOURLY VARIABILITY OF CEREBROSPINAL FLUID BIOMARKERS IN ALZHEIMER PATIENTS AND HEALTHY ELDERLY CONTROLS
D.Slats (1,6,7), J.Claassen (1,6,7), P.Spies (1,6,7), G.Borm (2), T.Besse (3), W.Van Aalst (1,6), J.Tseng (8), M.Sjögren (1,6), M.Olde Rikkert (1,6,7), M.Verbeek (4,5,6)

(1) Radboud University Nijmegen Medical Centre Department of Geriatric Medicine

(2) Department of Epidemiology, Biostatistics and HTA

(3) Department of Anesthesiology

(4) Department of Neurology

(5) Department of Laboratory Medicine, Nijmegen, The Netherlands

(6) Alzheimer Centre Nijmegen, Nijmegen, The Netherlands

(7) Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands

(8) Merck Research Labs, Kenilworth, NJ, USA

- O14** HOW BIOMARKERS CAN HELP INVESTIGATORS AND THE PHARMACEUTICAL INDUSTRY IN AD CLINICAL TRIALS. FROM CONCEPT TO APPLICATION

S.Gauthier (1), O.Sol (2), J.C.Lemarié (3), M.Pando (2)

(1) McGill Centre for Studies in Aging, Verdun, Québec, Canada

(2) ExonHit Therapeutics, Paris, France

(3) Effi-Stat, Paris, France

- O16** AMYLOID-BETA ASSOCIATED CORTICAL THINNING IN CLINICALLY NORMAL ELDERLY
K.A.Johnson, T.Hedden, R.L.Buckner, R.A.Sperling, J.A.Becker

Massachusetts General Hospital, Brigham and Women's Hospital Harvard Medical School

ORAL COMMUNICATIONS

THEME: Methodological aspects and treatment issues

Chaired by M.Boada, A.D.Roses

Chapelle Room

THEME: Biomarkers

Chaired by P.Robert, L.Frölich

Les Colonnnes Room

3.20 p.m

O17 TIME COURSE OF COGNITIVE DECLINE IN SUBJECTS WITH PRE-DEMENTIA ALZHEIMER'S DISEASE AND MILD ALZHEIMER'S DISEASE BASED ON ADAS-COG SUBSCALES AND NEUROPSYCHOLOGICAL TESTS
S.B.Hendrix, B.M.Wells
Pentara Corporation, Salt Lake City, UT, USA

O18 IDENTIFICATION OF BLOOD TRANSCRIPTOMIC SIGNATURES IN AD PATIENTS RELATED TO EHT 0202 TREATMENT RESPONSE AND EFFICACY
R.Einstein (2), P.Beurdeley (1), J.-C.Lemarie (3), E.Blondiaux (3), O.Sol (1), J.Carrière (1), R.Haddad (1), L.Désiré (1), M.Pando (1)
(1) ExonHit Therapeutics SA, Paris, France, (2) ExonHit Therapeutics, Inc., Gaithersburg, USA, (3) Effic-Stat, Paris, France

3.35 - 4.00 p.m

Coffee Break

4.00 p.m

O19 A PHARMACOGENETIC-ASSISTED ALZHEIMER'S DISEASE DELAY OF ONSET TRIAL DESIGN WITH DIAGNOSTIC PREDICTOR VALIDATION
A.D.Roses (1), K.Welsh-Bohmer (2), O.Makeeva (1), S.Brewster (1), J.Altman (1), J.Aruckle (1), Y.Maryama (1), A.Saunders (2), D.Crenshaw (2), M.Lutz (2), D.K.Burns (2)
(1) Zinfandel Pharmaceuticals, INC, (2) Duke university, Durham, USA

O20 TOWARDS A MOLECULAR ANALYSIS OF A-SYNUCLEIN PROTEIN IN CEREBROSPINAL FLUID
E.Vanmechelen, H.Decraemer Hilde, S.De Mey, C.Cindy, P.Grognet, D.Jacobs
Innogenetics NV, Technologiepark Zwijnaarde 6, Gent-Zwijnaarde

4.15 p.m

O21 PLASMA EXCHANGE WITH 5% HUMAN ALBUMIN FOR AMYLOID-B MOBILIZATION IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE
M.Boada, Barcelona, Spain

O22 EVP-6124 FUNCTIONS AS A POTENT NICOTINIC ALPHA7 CO-AGONIST WITH ACETYLCHOLINE AND ACTS SYNERGISTICALLY WITH ACHEIS IN COGNITION MODELS: IMPLICATIONS FOR COMBINATION THERAPY IN ALZHEIMER'S DISEASE
D.Hilt, N.van Goethem, J.Prickaerts, D.Bertrand, S.Bertrand, G.Shapiro, M.Gawryl, G.Koenig
Dr. Hilt EnVivo Pharmaceuticals Inc, Watertown, MA, USA

4.30 p.m

O23 WHY HAVE WE FAILED TO CURE ALZHEIMER'S DISEASE?
A.Korczyn, Tel-Aviv University Medical School, Israel

4.45 p.m

CLOSING KEYNOTE

Les Colonnnes Room

MABT5102A IS AN EFFECTOR-REDUCED ANTI-AB ANTIBODY WITH UNIQUE BINDING PROPERTIES THAT PROMOTES NEUROPROTECTION AND GLIAL ENGULFMENT OF AB
R.J.Watts (1), O.Adolfsson (2), A.Pfeifer (2), A.Muhs (2)
(1) Genentech Inc., South San Francisco, USA, (2) AC Immune SA, Lausanne, Switzerland

POSTERS

- P1** GRAPHICAL METHOD FOR THE PRESENTATION OF MULTIVARIATE TEST SCORE DATA
G. G. Crans
Elian Pharmaceuticals, South San Francisco, USA
- P2** A PROTEOMIC APPROACH FOR SEARCH AND IDENTIFICATION OF SURROGATE BLOOD BIOMARKERS FOR ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT
A. Matsumoto (1), H. Tsumoto (1), N. Shikaku (1), M. Toyomoto (1), R. Matsumoto (2), H. Sugimoto (1)
(1) Graduate School of Pharmaceutical Sciences, Kyoto University
(2) Medical Corporation Midorikawa Clinic of Neurology Kyoto, Japan
- P3** PATIENT VERSUS INFORMANT REPORTS ON PERSONALITY IN SUBJECTIVE COGNITIVE IMPAIRMENT AND MILD COGNITIVE IMPAIRMENT
N. Bogdanovic (1), B. Ausén (1), G. Edman (2), O. Almkvist (1,3)
(1) Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
(2) Department of Psychiatry, Danderyd Hospital, Stockholm, Sweden, (3) Department of Psychology, Stockholm University, Stockholm, Sweden
- P4** ANTEMORTEM MODELING OF BRAAK & BRAAK NEUROPATHOLOGY
R. E. Tractenberg
Departments of Neurology, Biostatistics, Bioinformatics & Biomathematics, and Psychiatry; Georgetown University Medical Center, Washington DC, USA
- P5** THE OMEGA-3 FATTY ACID, DHA, ACTS THROUGH A ZINC-DEPENDENT MECHANISM TO PREVENT NEURONAL CELL DEATH
D. De Mel (1), C. Suphioglu (1), L. Kumar (1), N. Sadli (1), D. Freestone (1), A. Michalczyk (1), A. Sinclair (2), M. Leigh Ackland (1)
(1) School of Life and Environmental Sciences, Burwood, Victoria 3125, Australia
(2) School of Exercise and Nutrition Sciences, Deakin University, 221 Burwood Highway, Burwood, Victoria 3125, Australia
- P6** THE LONGITUDINAL CHANGES OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE – CSF HYPERPHOSPHORYLATED TAU DECREASES IN CONNECTION WITH COGNITIVE DECLINE DURING THE AD PROCESS
T. Seppälä, A. Koivisto, P. Hartikainen, S. Helisalmi, H. Soininen, S. K. Herukka
University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland
- P7** OPTIMIZATION OF THE TREATMENT REGIMEN WITH ACTIVE ASS IMMUNOTHERAPY CAD106 IN ALZHEIMER PATIENTS
G. Imbert (1), N. Andreasen (2), M. E. Riviere (1), J. Ros (1), J. Moreau (1), J. Sevigny (1), P. Quarg (1), A. Caputo (1), L. A. Finelli (1), B. Winblad (2), A. Graf (1)
(1) Novartis Pharma AG, Basel, Switzerland
(2) Karolinska Universitetssjukhuset, Huddinge, Sweden

POSTERS

- P8** SURVEY OF SEGMENTATION PROTOCOLS FOR MANUAL HIPPOCAMPAL VOLUMETRY: PREPARATORY PHASE FOR AN EADC-ADNI HARMONIZATION EFFORT
M.Boccardi, R.Ganzola, S.Duchesne, N.Robitaille, M.Bocchetta, A.Redolfi, G.Bartzokis, J.G. Csernansky, M.J.De Leon, L.DeToledo-Morrell, R.J.Killiany, S.Lehéricy, R.Camicoli, J.Pantel, J.C.Pruessner, H.Soininen, C.Watson, C.Jack, G.B.Frisoni
IRCCS – S. Giovanni di Dio – Fatebenefratelli Brescia, Italy (MB, RG, AR, GBF)
Université Laval and Centre de Recherche Université Laval – Robert Giffard, Quebec City, Canada (SD, NR), David Geffen School of Medicine at UCLA, Los Angeles, CA (GB), Northwestern University Feinberg School of Medicine, Chicago, IL, USA (JGC), Center for Brain Health, New York, NY (M.JdL), Rush University, Chicago, Illinois (LdTM)
Boston University School of Medicine (RJK), CENIR and Dept of Neuroradiology, Université Pierre et Marie Curie-Paris 6, Groupe Hospitalier Pitié-Salpêtrière, Paris, France (SL), University of Alberta, Edmonton, Alberta, Canada. (NVM), University of Frankfurt/Main, Germany (JP), McGill Centre for Studies in Aging, Department of Psychiatry, McGill University, Montreal, Quebec, Canada (JCP), Kuopio University Hospital, Kuopio, Finland (HS), Wayne State University School of Medicine, 8D-University Health Center, St. Antoine, Detroit, MI (CW), Mayo Clinic and Foundation, Rochester, MN (CJ)
- P9** COGNITIVE PERFORMANCE, FUNCTIONAL ABILITY AND NEUROPSYCHIATRIC SYMPTOMS OF PATIENTS WITH ALZHEIMER'S DISEASE
I.Hallikainen (1), A.Hiltunen (2), T.Hänninen (3), P.Karppi (4), T.Paajanen (1), H.Soininen (1,3), M.Vanhanen (5), T.Välimäki (6), T.Pirttilä (1,3)
(1) Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland, (2) Department of Neurology, North Karelia Central Hospital, Joensuu, Finland (3) Department of Neurology, Kuopio University Hospital, Kuopio, Finland, (4) Mikkeli Central Hospital, Mikkeli, Finland (5) Niuvanniemi Hospital, Kuopio, Finland, (6) Department of Nursing Sciences, University of Eastern Finland, Kuopio, Finland
- P10** MARKERS OF DISEASE PROGRESSION: FROM MCI TO AD
V.Drago, M.Pievani, C.Babiloni, A.Caroli, L.Venturi, P.Spitzer, J.Wiltfang, M.Didic, H.Klaffki, F.Vecchio, A.Redolfi, G.B.Frsioni
Laboratorio LENITEM, I.R.C.C.S. San Giovanni di Dio Fatebenefratelli, Brescia, Italy
- P11** THE EFFECT OF 17-B-ESTRADIOL ON THE EXPRESSION OF NEUROPROTECTIVE FACTORS IN CULTURED ASTROCYTES
A.Pirouzi, M.Mohsenzadeh, M.Jaffari, A.Abdollahi, Z.Yarahmadi
Health Department, Gerash University of Medical Sciences, Gerash, Iran
- P12** PHYSICAL ACTIVITY AS A PROTECTIVE FACTOR IN A PROSPECTIVE AGEING STUDY IN GERMANY
J.Schröder, C.Sattler, H.Jilg, P.Toro
Section of Geriatric Psychiatry, University of Heidelberg, Heidelberg, Germany
- P13** GLUTAMINYL CYCLASE AS NOVEL PHARMACOLOGICAL TARGET FOR AD THERAPY
S.Roßner (1), M.Hartlage-Rübsamen (1), S.Schilling (2), H.U.Demuth (2)
(1) University of Leipzig, Medical Faculty, Leipzig, Germany (2) Probiodrug AG, Halle/S., Germany
- P14** THE EFFECT OF DCNP ON AMYLOID BETA PEPTIDE TOXICITY AND PREGNENOLONE SULFATE SYNTHESIS
P.Akan, O.G.Calan, M.Ormen, M.Fadiloglu
Department of Medical Biochemistry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

POSTERS

- P15** NUTRITIONAL AND PSYCHO-FUNCTIONAL STATUS IN ELDERLY PATIENTS WITH ALZHEIMER'S DISEASE
B.Saragat (1), R.Buffa (1), R.M.Mereu (2), D.Viale (2), P.F.Putzu (2), E.Marini (1)
 (1) Department of Experimental Biology, Anthropological Science Section, University of Cagliari, Italy;
 (2) Geriatric Division, SS Trinità Hospital, ASL 8, Cagliari, Italy
- P16** SPOKEN LANGUAGE AS AN INDICATOR OF RISK FOR ALZHEIMER'S DISEASE: ANALYSES OF BIOGRAPHICAL INTERVIEWS OF A LONGITUDINAL AGEING STUDY IN GERMANY
B.Wendelstein (1,2,3), E.Felder (2,3), J.Schröder (1,3)
 (1) Section of Geriatric Psychiatry, University of Heidelberg, Heidelberg, Germany
 (2) Germanistisches Seminar, University of Heidelberg, Germany
 (3) Marsilius-Kolleg, University of Heidelberg, Germany
- P17** THE RELATIONSHIP OF HEMOGLOBIN AND COGNITIVE FUNCTION IN THE ELDERLY KOREAN
Moon Ho, Park
 Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea
- P18** LOOKING FOR ALZHEIMER'S DISEASE VESTIGE IN THE MEMORY OF PERIPHERAL BLOOD
F.Ciccocioppo (1,2), A.Thomas (1,2), P.Lanuti (3,4), L.Bonanni (1,2), D.Monaco (1,2), S.Bifolchetti (1,2), M.C.D'Amico (1,2), I.Borrelli (1,2), M.Marchisio (3,4), L.Pierdomenico (3,4), D.Gambi (1,2), F.Kern (5), S.Miscia (3,4), M.Onofri (1,2)
 (1) Department of Neuroscience and Imaging, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy
 (2) Behavioural Neurology and Movement Disorders Unit, Aging Research Centre (Ce.S.I.), "Università G. d'Annunzio" Foundation, Chieti, Italy
 (3) Cell Signalling Unit, Department of Medicine and Aging Sciences, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy
 (4) Cytomorphology Unit, Aging Research Centre (Ce.S.I.), "Università G. d'Annunzio" Foundation, Chieti, Italy
 (5) Division of Medicine, Brighton and Sussex Medical School, Brighton, UK
- P19** CHOLESTEROL PROFILE IN ALZHEIMER'S DISEASE
J.Jafarbay (1), H.Anglaret (2), M.Saber (1), J.J.Arviu (1)
 (1) Centre hospitalier de Gériatrie « Les Abondances » 56, rue des Abondances.92100 Boulogne Billancourt. France
 (2) Hôpital Saint Cloud, France
- P20** HIPPOCAMPAL ATROPHY IN SUBCORTICAL VASCULAR DEMENTIA
H.olf (2,3), L.Van de Pol (1), H.J.Gertz (2), Ph.Scheltens (1)
 (1) Department of Neurology and Alzheimer Center, VU University Medical Center Amsterdam, PO Box 7057, 1007 MB Amsterdam, The Netherlands
 (2) Department of Psychiatry, University of Leipzig, Memory Clinic, Johannisallee 34, 04103 Leipzig, Germany, Germany
 (3) Department of Psychiatry Research and Geriatric Psychiatry at the Psychiatric University Hospitals (PUK), University of Zurich, Switzerland

POSTERS

- P21** STUDY DESIGN OF THE “12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BUPROPION FOR THE TREATMENT OF APATHY IN ALZHEIMER’S DEMENTIA (APA-AD)”
A. Spottke (1,2), M. Mahne (5), H. Stützer (6), K. Bürger (7), R. Dodel (8), A. Heinz (9), I. Heuser (10), H. Jahn (11), J. Kornhuber (12), O. Peters (10), J. Schröder (13), J. Wiltfang (14), M. Hüll (4), L. Frölich (3), F. Jessen (2)
*(1) Department of Neurology, University of Bonn, Germany, (2) Department of Psychiatry, University of Bonn, Germany
(3) Central Institute for Mental Health, Mannheim, Germany, (4) Center for Geriatric Psychiatry, University of Freiburg, Germany
(5) Center for Clinical Trials Cologne, Germany, (6) Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Germany
(7) Institute for Stroke and Dementia Research, University of Munich, Germany, (8) Department of Neurology, University Marburg, Germany
(9) Department of Psychiatry, Charité Campus Mitte, Germany, (10) Department of Psychiatry, Charité Campus Benjamin Franklin, Germany
(11) Department of Psychiatry, University of Hamburg, Germany, (12) Department of Psychiatry, University of Erlangen, Germany
(13) Department of Psychiatry, University of Heidelberg, Germany, (14) Department of Psychiatry, University of Essen, Germany*
- P22** MULTIFACTORIAL COGNITIVE TRAINING INTERVENTION IN AMCI
C. Latger-Florence (1), E. Tramoni (1, 2), C. Arnaud (1), E. Da Fonseca (1), M. Ceccaldi (1,2)
*(1) Service de Neurologie et de Neuropsychologie, CHU Timone, Marseille, France
(2) Laboratoire Epilepsies et Cognition, INSERM U 751, Faculté de Médecine, Marseille*
- P23** MANAGING RATER DRIFT and RATINGS ERRORS WITH IN-STUDY RATINGS SURVEILLANCE
D. S. Miller, P. Samuelson, J. Carpenter, K. Foulds
United BioSource Corporation, Wayne, PA, USA
- P24** INTRAINDIVIDUAL VARIABILITY & NEUROPATHOLOGY FOR STUDY OF AD, MCI AND BRAIN AGING
R. E. Tractenberg
Departments of Neurology, Biostatistics, Bioinformatics & Biomathematics, and Psychiatry; Georgetown University Medical Center, Washington DC, USA
- P25** PREDICTING COGNITIVE DECLINE IN PATIENTS WITH PRE-SYMPTOMATIC AD: THE PLACEBO GROUP SIMULATION APPROACH
R. Spiegel, M. Berres, A. U. Monsch, A. R. Miserez
Memory Clinic, Geriatric University Hospital, Basel (Switzerland)
- P26** sAPP β IS SIGNIFICANTLY CORRELATED WITH TAU PROTEIN IN THE CEREBROSPINAL FLUID: A LINK BETWEEN β -AMYLOID AND TAU PATHOLOGY IN ALZHEIMERS’S DISEASE?
P. Alexopoulos (1,2), A. Tsolakidou (1), F. Roselli (3), T. Eisele (1), C. Westerteicher (1), A. Arnold (1), H. Förstl (2), A. Kurz (2), R. Perneczky (1,2)
*(1) Neurobiological Laboratory, Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany
(2) Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany
(3) Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy*
- P27** PERIVENTRICULAR WMHS ARE RELATED TO VASCULAR RISK—EVEN IN ADNI
C. De Carli, D. Harvey, L. Beckett, C. Schwarz, D. Drucker, E. Fletcher, O. Carmichael
Imaging of Dementia and Aging laboratory, Department of Neurology and Center for Neuroscience, University of California at Davis. Davis, California, USA

POSTERS

- P28** IMPACT OF CLINICAL ACCURACY IN DEVELOPMENT AND VALIDATION OF A BLOOD BASED TEST FOR EARLY DETECTION OF ALZHEIMER'S DISEASE
A.Lönneborg, G.Grave, B.B.Booij, P.D.Rye, L.Kristiansen, T.Lindahl, P.Sharma
Diagenic Asa, Oslo, Norway
- P29** INVECE.AB : A MULTIDIMENSIONAL POPULATION STUDY ON BRAIN AGING FOR THE 1935 – 1939 BORN PEOPLE, IN A SMALL TOWN NEAR MILAN
A.Guaita (1), G.L.Forloni (2), V.Ferretti (3), S.Villani (3), S.Fossi (1), M.Colombo (4), G.Salvini Porro (5)
(1) Golgi Cenci Research Foundation, Abbiategrosso, Milano, (2) Mario Negri Institute of Pharmacological Research, Milan
(3) Department of Health Sciences, Section of Epidemiology and Medical Statistic Pavia University, Pavia, (4) Geriatric Institute "Camillo Golgi", Abbiategrosso
(5) Federazione Alzheimer Italia, Milan
- P30** PHARMACOLOGICAL ENHANCEMENT OF NEUROGENESIS AND NEURONAL PLASTICITY: A NEW THERAPEUTIC APPROACH AWAITING CLINICAL TRIALS
I.Grundke-Iqbal, J.Blanchard, K.Iqbal
New York State Institute For Basic Research In Developmental Disabilities Staten Island, New York, U.S.A
- P31** FACTORS INFLUENCING LONGITUDINAL COSTS IN MILD TO MODERATE ALZHEIMER DISEASE: RESULTS FROM THE PLASA STUDY
T.Rapp, S.Andrieu, B.Vellas
Insem U558 & Gerontopole, Toulouse, France
- P32** STABILITY OF DIFFERENT BIOMARKER PROTEINS IN LONG-TERM STORED HUMAN CEREBROSPINAL FLUID FROM AD PATIENTS
O.Peters (1), I.Heuser (1), J.Kornhuber (2), L.Frölich (3), C.G.Schipke (1)
(1) Department of Psychiatry, Charité-CBF, Berlin, Germany
(2) Department of Psychiatry, University Erlangen, Germany
(3) CIMH, Mannheim, Germany
- P33** BAPINEUZUMAB PHASE 3 TRIALS IN MILD-TO-MODERATE ALZHEIMER'S DISEASE: TRIAL DESIGN FOR A POTENTIAL DISEASE MODIFYING THERAPY
E.Liu (1), R.Black (2), K.Gregg (1), M.Grundman (1), for the ELN115727-301/302 Investigator Group
(1) JANSSEN Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, CA, USA
(2) Pfizer Inc, Collegeville, PA, USA
- P34** THE ECOG CORRELATES WITH COGNITIVE AND FUNCTIONAL PERFORMANCE
S.Farias (1), G.Crans (2), R.Motalli (3), T.E.Liu (3), R.Black (4), M.Grundman (3) for the ELN-AIP-901 Study Investigator Group
(1) University of California, Davis
(2) Elan Pharmaceuticals, Inc., South San Francisco, CA, USA
(3) Janssen Alzheimer Immunotherapy, South San Francisco, CA 4Pfizer, Collegeville, PA, USA

POSTERS

- P35** NEW MODELS OF A β OLIGOMER-INDUCED COGNITIVE IMPAIRMENT AND SYNAPTIC DEGENERATION FOR MOLECULE SCREENING AND THERAPEUTIC TARGETS IDENTIFICATION
C.Malaplate-Armand, V.Koziel, F.T.Yen, M.C.Escanyé, T.Oster, T.Pillot
 SynAging SAS, Nancy, France
- P36** INHIBITION OF GLUTAMINYL CYCLASE(S) TARGET BOTH – NEURODEGENERATION AND NEUROINFLAMMATION – IN ALZHEIMER'S DISORDER
H.U.Demuth (1), H.Cynis (1), A.Alexandru (2), A.Becker (2), W.Jagla (2), S.Graubner (2), S.Schilling (1)
 (1) Probiodrug AG, Halle/Saale, Germany
 (2) Ingenium Pharmaceuticals GmbH, Munich-Martinsried, Germany
- P37** EXPERIMENTAL PROTOCOL OF THEORETICAL BASE FOR THE RECOVERY OF INCIPIENT CASES OF THE INDIVIDUAL SO CALLED ALZHEIMER PROCESS AT SOUTH AMERICA
L.M.Sanchez, J.D.Garcia, P.del C.Tudor, J.A.Villarreal, D.Prieto, M.A.Leites, G.A.Martinez, E.D.Ferrari, M.A.Jalife, N.E.Santa Cruz, J.Gomez Salgado, C.Niemz, C.R.Cantero
 Neuro-psycho-ethology Research Center, University of Entre Rios, Argentine
- P38** COGNITIVE TRAINING OF ATTENTION AND EXECUTIVE FUNCTION IN PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT
M.Tsolaki (1,2), F.Kounti (1,4), C.Agogiatiou (1), A.Soubourou (1), M.Zafeiropoulou (1,3), E.Poptsi (1), E.Bakoglidou (1), S.Zafeiropoulos (1), G.Batsila (1), E.Nikolaidou (1), G.Kiosseoglou (4), A.Efklides (4)
 (1) Greek Association for Alzheimer's disease
 (2) Medical School Aristotle University of Thessaloniki
 (3) Department of Psychology
 (4) New York College, Department of Psychology
 (5) Aristotle University of Thessaloniki
- P39** LATIN AMERICA A SUCCESSFUL EMERGING MARKET FOR ALZHEIMER'S DISEASE CLINICAL RESEARCH
F.Manes (1), F.Lerner (2)
 (1) Director, Institute of Neurosciences - Favaloro University and Director, Institute of Cognitive Neurology (INECO); Buenos Aires, Argentina
 (2) Sr Director of Operations, Latin America; PRA International; Buenos Aires, Argentina
- P40** USE OF ANTIPSYCHOTICS IN BEHAVIOURAL DISORDERS IN DEMENTIA
P.Gareri (1,2), P.De Fazio (3), N.M.Marigliano (1), R.Lacava (2), A.Castagna (2), D.S.Costantino (2), G.De Sarro (1)
 (1) Chair of Pharmacology and Psychiatry³, Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, University Magna Graecia of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital, 88100 Catanzaro, Italy
 (2) Geriatrist, Operative Unit Elderly Health Care, 88100 Catanzaro, Italy

POSTERS

- P41** VOXEL-BASED LONGITUDINAL CHANGES OF GRAY MATTER DENSITY IN INCIPIENT ALZHEIMER'S DISEASE
M.Lorenzi, G.B.Frisoni, The Alzheimer's Disease Neuroimaging Initiative
 LENITEM Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS San Giovanni di Dio-FBF, Brescia, Italy
- P42** THE ENHANCEMENT OF THE CAPACITY OF HUMAN BODY TO TAKE ENERGY FROM WATER IMPROVES SIGNIFICANTLY THE PATIENTS WITH ALZHEIMER'S DISEASE
A.Solis Herrera, M.del C.Arias Esparza, I.Ruth Solis Arias, E.Paola Solis Arias, M.P.Solis Arias
 Human Photosynthesis Study Center, Aguascalientes, Mexico
- P43** BEHAVIORAL-BASED SCREENING OF DRUG CANDIDATES FOR ALZHEIMER'S DISEASE TREATMENT
Y.Zhong (2), Z.L.Xie (1), W.W.Ma (1)
 (1) JoeKai Biotech. LLC, Beijing, China
 (2) Cold Spring Harbor Lab., Cold Spring Harbor, NY 11724 USA
- P44** HDL, LDL AND TOTAL CHOLESTEROL IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE RESULTS FROM THE ILSE-STUDY
J.Schröder, C.Sattler, P.Schönknecht, P.Toro
 Section of Geriatric Psychiatry, University of Heidelberg, Heidelberg, Germany
- P45** DIABETES AS A RISK FACTOR FOR MILD COGNITIVE IMPAIRMENT IN A POPULATION-BASED SAMPLE IN GERMANY
J.Schröder, C.Sattler, P.Schönknecht, P.Toro
 Section of Geriatric Psychiatry, University of Heidelberg, Heidelberg, Germany
- P46** DEFAULT MODE NETWORK IS AFFECTED IN ALZHEIMER'S DISEASE AS SHOWN BY BRAIN OSCILLATORY RESPONSES
G.G.Yener (1), B.Güntekin (2), E.Başar (2)
 (1) Dokuz Eylül University, Departments of Neurology and Neurosciences, Brain Dynamics Multidisciplinary Research Center, Izmir 35340, Turkey
 (2) Istanbul Kultur University, Brain Dynamics, Cognition and Complex Systems Research Center, Istanbul 34156, Turkey
- P47** PLASMA LONG-CHAIN OMEGA-3 FATTY ACIDS AND TRAJECTORIES OF COGNITIVE DECLINE AMONG OLDER SUBJECTS WITH A SUBJECTIVE MEMORY COMPLAINT AND MMSE SCORE ABOVE 24
C.Samieri, C.Proust-Lima, C.Féart, P.Barberger-Gateau
 Research Center Inserm, U897, ISPED, University Bordeaux 2, Bordeaux, France
- P48** AN EASY AND CONVENIENT WAY TO RECRUIT INDIVIDUALS FOR CLINICAL TRIALS IN ALZHEIMER DISEASE
P.Pesini (1), I.Monleón (1), V.Pérez-Grijalba (1), A.M.Lacosta (1), I.San José (1), M.Boada (2), P.Martínez-Lage (2), L.Tárraga (2), M.L.Suárez (3), G.Santamarina (3), M.Sarasa (1)
 (1) Aracón Biotech Ltd, Zaragoza, Spain
 (2) Fundación ACE, Barcelona, Spain
 (3) Hospital universitario veterinario Rof Codina, Lugo, Spain

POSTERS

- P49** THE PARADOX OF ANTIPSYCHOTIC DRUGS IN ALZHEIMER'S DISEASE: THE PREMATURE INTERRUPTION OF A RANDOMIZED CONTROLLED TRIAL
F.Galeotti, N.Vanacore, F.Izzicupo, S.Gainotti, F.Menniti-Ippolito, R.Raschetti and the AdCare study group
National Centre for Epidemiology, Surveillance and Health Promotion, National Institute of Health, Rome, Italy
- P50** RELATIONAL FACTORS OF SUBJECTIVE WELL-BEING IN OLD AGE
R.Moraru, L.Spiru, M.Blacioti
Ana Aslan International Academy of Aging, Bucharest, Romania
- P51** ALZHEIMER'S DISEASE: A BRAIN'S DIABETES?
A.G.Diaconeasa, L.Spiru, I.Turcu
Ana Aslan International Academy of Aging, Bucharest, Romania
- P52** CLINICAL TRIALS FOR PATIENT PROFILING AND VALIDATION OF AMBIENT INTELLIGENCE ASSISTIVE DEVICES
L.Spiru, I.Turcu, C.Ghita
Ana Aslan International Academy of Aging, Bucharest, Romania
- P53** ABILITY TO CONSENT TO BIOMEDICAL RESEARCH 'S EVALUATION AMONG ELDERLY COGNITIVELY IMPAIRED PATIENTS
E.Duron, M.Boulay, A.Rigaud, L.Hugonot-Diener
Broca university hospital, Paris, France
- P54** FIRST RESULTS OF ASCOMAVA TRIAL ON THE ASSOCIATION BETWEEN THE CHOLINESTERASE INHIBITOR DONEPEZIL AND THE CHOLINERGIC PRECURSOR CHOLINE ALPHOSCERATE IN ALZHEIMER'S DISEASE
F.Amenta (1), A.Carotenuto (1), R.Rea (1), E.Traini (1), A.M.Fasanaro (2)
(1) Centro Ricerche Cliniche, Telemedicina e Telefarmacia, Università di Camerino, 62032 Camerino
(2) Unità Valutativa Alzheimer e Malattie Involutive Cerebrali, Azienda Ospedaliera Rilievo Nazionale A. Cardarelli, 80131 Napoli, Italy
- P55** EFFECT OF MEMANTINE ON RESTING STATE DEFAULT MODE NETWORK ACTIVITY IN ALZHEIMER'S DISEASE
M.Lorenzi (1), A.Beltramello (2), N.B.Mercuri (3), E.Canu (1), G.Zoccatelli (2), F.B.Pizzini (2), F.Alessandrini (2), M.Cotelli (4), S.Rosini (4), D.Costardi (1), C.Caltagirone (3), G.B.Frisoni (1)
(1) LENITEM, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy
(2) Service of Neuroradiology, Ospedale Maggiore, Borgo Trento, Verona, Italy
(3) Fondazione IRCCS, Santa Lucia, Università Tor Vergata, Rome, Italy
(4) Cognitive Neuroscience Section, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy



SPONSORS

Many thanks to our major sponsors :



GENERAL INFORMATION

CONGRESS VENUE: Dieu Saint Jacques Hotel
2 rue Viguerie 31000 TOULOUSE

OPENING HOURS: Congress registration desk
Wednesday, November 3rd: 8 a.m. to 7 p.m.
Thursday, November 4th: 7.30 a.m. to 7 p.m.
Friday, November 5th: 8 a.m to 5.30 p.m.

LUNCHES: The lunches on Thursday and Friday (included in your registration) will take place in the room with the poster sessions.

WELCOME RECEPTION: The welcome reception will take place at the Toulouse City Hall, Place du Capitole.

CME: This training is part of the 1st category of attendance training according to the law of July 13th 2006, defining the validation rules of Continuing Medical Education and leading to the attribution of 20 credits.

POSTERS: Posters will be displayed where coffee breaks and lunches are being held and listed by abstract number.

- poster display : Wednesday from 2.00 up to 5 p.m
- poster take-out: Friday from 2.30 up to 5.30 p.m

Fixing supplies will be handed out to you onsite at the congress secretariat (welcome/registration counter)

SPEAKERS: Please go directly to the room where your talk is scheduled during coffee or lunch breaks in order to pre-download your presentation. If you have sent your presentation directly to the Congress Secretariat please make sure that all is correctly SET UP.

CAR PARKING

Parking Place du Capitole at a walking distance from all hotels
Walking distance to the Congress venue: Place du capitole
Congress venue: 10 mn



RECOMMENDED HOTELS:

1- Crowne Plaza Toulouse****

7, place du Capitole
Tel. : +33 (0)5 61 61 19 19

2- Grand Hôtel de l'Opéra****

1 Place du Capitole
Tel. : +33 (0)5 61 21 82 66

3- Hôtel Le Grand Balcon****

8 rue Romiguières
+33 (0)5 34 25 44 09

4- Hôtel Les Beaux Arts***

1 Place du Pont Neuf
+33 (0)5 34 45 42 82

5- Hôtel Garonne***

22 descente de la Halle-aux-Poissons
+33 (0)5 34 31 94 80

CTAD 2011

Clinical Trials on Alzheimer's Disease

Montpellier '08 | Las Vegas '09 | Toulouse '10 | San Diego '11

Clinical Trials on Alzheimer's Disease

November 3-5, 2011

San Diego

<http://www.ctad.fr>



**CTAD
San Diego
2011**

Clinical Trials



European Alzheimer's Disease Consortium
Montpellier and Toulouse EADC Centers


UC San Diego
SCHOOL OF MEDICINE